Roivant Sciences/$ROIV
Shares rise after Roivant and Priovant announced positive Phase 3 VALOR results for brepocitinib in dermatomyositis, with the 30 mg dose achieving significant improvement and NDA filing planned for 1H 2026.
15 hours agoLightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
$ROIV
Sector
Primary listing
Employees
750
Headquarters
Website
Roivant Sciences Metrics
BasicAdvanced
$9.7B
-
-$0.69
1.15
-
Price and volume
Market cap
$9.7B
Beta
1.15
52-week high
$14.48
52-week low
$8.73
Average daily volume
6.4M
Financial strength
Current ratio
40.537
Quick ratio
39.548
Long term debt to equity
1.875
Total debt to equity
2.07
Profitability
EBITDA (TTM)
-1,139.561
Gross margin (TTM)
-2,385.16%
Net profit margin (TTM)
-2,111.79%
Operating margin (TTM)
-4,998.84%
Effective tax rate (TTM)
-4.39%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-12.50%
Return on equity (TTM)
-18.15%
Valuation
Price to revenue (TTM)
434.277
Price to book
2.23
Price to tangible book (TTM)
2.23
Price to free cash flow (TTM)
-11.75
Free cash flow yield (TTM)
-8.51%
Free cash flow per share (TTM)
-1.207
Growth
Revenue change (TTM)
-35.86%
Earnings per share change (TTM)
-112.22%
3-year revenue growth (CAGR)
-23.49%
3-year earnings per share growth (CAGR)
-24.50%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Bulls say / Bears say
Roivant's loss from continuing operations widened to $252.4 million in the fourth quarter ended March 31, 2025, compared with $95.0 million a year earlier, challenging its path to profitability (BioSpace)
Research and development expenses surged by $37.7 million to $145.2 million for the quarter ended March 31, 2025, further increasing its cash burn (BioSpace)
Ongoing lipid nanoparticle (LNP) patent litigation against Moderna has entered the summary judgment phase, with a jury trial set for March 2026, presenting potential legal liabilities and distraction for management (GLOBE NEWSWIRE)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Roivant Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roivant Sciences stock?
Roivant Sciences (ROIV) has a market cap of $9.7B as of September 18, 2025.
What is the P/E ratio for Roivant Sciences stock?
The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 0 as of September 18, 2025.
Does Roivant Sciences stock pay dividends?
No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Roivant Sciences dividend payment date?
Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.
What is the beta indicator for Roivant Sciences?
Roivant Sciences (ROIV) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.